User profiles for S. Lockhart

Stephen Lockhart

- Verified email at pfizer.com - Cited by 27409

Shawn R Lockhart

- Verified email at cdc.gov - Cited by 23745

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive …

…, D Andes, MC Arendrup, SD Brown, SR Lockhart… - Drug Resistance …, 2011 - Elsevier
… ), 58% (ANF) and 66% (MCF) had MICs in the S category using CBP of ≤2 mcg/ml, while
0–8% would be S using CBP of ≤0.25 mcg/ml. WT MIC distributions revealed ECV ranges of …

Fluconazole resistance in Candida species: a current perspective

EL Berkow, SR Lockhart - Infection and drug resistance, 2017 - Taylor & Francis
… Further characterization of the cause(s) of increased ERG11 expression is needed in these
… It is possible that a mutation in a putative import transporter could impair the cell’s ability to …

Changes in the epidemiological landscape of invasive candidiasis

F Lamoth, SR Lockhart, EL Berkow… - Journal of …, 2018 - academic.oup.com
The epidemiology of invasive candidiasis has evolved in recent years, warranting a review
of the changes and the implications for current and future diagnosis and treatment. The …

[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

…, J Absalon, A Gurtman, S Lockhart… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …

[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months

…, J Absalon, A Gurtman, S Lockhart… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …

[HTML][HTML] Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents

…, A Gurtman, J Absalon, S Lockhart… - … England Journal of …, 2021 - Mass Medical Soc
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …

[HTML][HTML] Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age

…, C Sabharwal, A Gurtman, S Lockhart… - … England Journal of …, 2022 - Mass Medical Soc
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …

Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses …

…, CJ Clancy, JR Wingard, SR Lockhart… - Clinical Infectious …, 2020 - academic.oup.com
… After completing the first round of working group assignments, leaders presented each
group’s initial deliberations and recommendations at the 7th Trends in Medical Mycology …

[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

…, J Absalon, A Gurtman, S Lockhart… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …

Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses

SR Lockhart, KA Etienne, S Vallabhaneni… - Clinical Infectious …, 2017 - academic.oup.com
… auris infections seem to be hospital acquired and occur several weeks into a patient’s hospital
stay, suggesting an exogenous rather than endogenous source and a breach of infection …